摘要
目的探讨致敏的树突状细胞联合化疗治疗晚期胃肠道恶性肿瘤的临床疗效和毒副作用。方法40例晚期的胃癌和结直肠癌患者随机分为树突状细胞联合化疗组(观察组)和单纯化疗组(对照组),治疗组化疗前分离患者外周血单核细胞,体外培养成致敏的树突状细胞,培养期间给予患者一周期的5-FU、CF和奥沙利铂方案的化疗,化疗后回输树突状细胞,对照组给予患者同一方案的化疗,观察临床获益率、卡氏评分和毒副作用等临床指标。结果两组临床获益率无统计学差异(P>0.05),骨髓抑制毒副反应较对照组明显减轻(P<0.05),观察组行树突状细胞回输时,常见的不良反应为发热,未发现III级以上的毒副作用。结论两组临床疗效相近,树突状细胞能够减轻化疗的毒副反应,改变免疫抑制状态,提高免疫功能,改善患者的生活质量。
Objective To observe the clinical curative effect and side effect of dendritic cell combined chemotherapy in advanced gastrointestinal cancer. Methods Forty patients with advanced gastric cancer or coloreetal cancer were randomly divided into chemotherapy group （control goup） and dendritic cell combined with chemotherapy group （observing group）, sensitized matured DCs were derived from peripheal blood monocytes of the patients in observing group before chemotherapy which were loaded tumor lysate and cultivated in vitro, in the course of cultivation, the patients in observing group received oxaliplatin （L- OHP） plus 5 -FU/CF, sensitized matured DCs were administered after chemotherapy, the patients in control group received the treatment of the same regimen, toxicity, clinical benefit response rate and KPS were obseved. Results No statistical difference was found in clinical benefit response rate between two groups （P 〉 0.05 ）. Compared with control group, bone marrow suppression was mild in obversing goup （P 〈 0. 05）. In observing group, when sensitized matured DCs were administered, fever was a common side effect, serious side effect was not obversed. Conclusions The response rate of bioehmotherapy is the same with chemotherapy;dendritic cell can decrease side effect of chemotherapy, change immunosuppression, enhance immune function and improve patients＇ quality of life.
出处
《医学信息（手术学分册）》
2008年第11期993-995,共3页
Medical Information Operations Sciences Fascicule
